<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04576494</url>
  </required_header>
  <id_info>
    <org_study_id>PO20136</org_study_id>
    <nct_id>NCT04576494</nct_id>
  </id_info>
  <brief_title>Study of the Functional Effects of Nusinersen in 5q-spinal Muscular Amyotrophy Adults (SMA Type 2 or 3 Forms)</brief_title>
  <acronym>NUSI-AD-5qSM</acronym>
  <official_title>Study of the Functional Effects of Nusinersen in 5q-spinal Muscular Amyotrophy Adults (SMA Type 2 or 3 Forms): a Multicenter Single-case Experimental Design in Multiple Baselines Across Subjects, Randomized, Single-blinded Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Reims</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Reims</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spinal Muscular Atrophy (SMA) is an autosomal recessive disease caused by a mutation of exon&#xD;
      7, in 95% of cases, encoding the gene for the motor neuron survival protein called SMN1&#xD;
      (Survival Motor Neuron) located on chromosome 5q. Patients with an SMA-5q mutation suffer&#xD;
      from progressive muscle deficiency and subsequent atrophy induced by degeneration of motor&#xD;
      neurons in the spinal cord. Gene therapy is now available for the management of spinal&#xD;
      muscular atrophy and nusinersen is the first approved treatment. Nusinersen has been granted&#xD;
      marketing authorization in France since May 30, 2017. Nusinersen has a high level of medical&#xD;
      service rendered (MSR) for types I, II, and III, but the improvement in medical service&#xD;
      rendered (IMSR) is assessed as moderate for types I and II. For Type III, IMSR is not known.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study will be to evaluate the impact on functional motor abilities of&#xD;
      intrathecally-injected nusinersen in adult 5q-SMA type 2 and type 3 persons.&#xD;
&#xD;
      If the efficacy of nusinersen protocol will demonstrate the positive impact for patient's,&#xD;
      the results of this study would promote an improvement in the medical service rendered in&#xD;
      this population in terms of disease stabilization, maintenance of functional capacities and&#xD;
      social participation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>functional motor ability</measure>
    <time_frame>19 months</time_frame>
    <description>functional motor abilities will be evaluate using the Motor Function Measure global score.&#xD;
The Motor Function Measure is composed of 32 items, sides from 0 to 3. A high score indicates a better motor function, which can reach a maximum of 96 points.&#xD;
The average duration of the test is about 40 minutes.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Spinal Muscular Atrophy</condition>
  <arm_group>
    <arm_group_label>5q-SMA type 2 and type 3 adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5q-SMA type 2 and type 3 adults</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Monthly assessments of functional motor abilities by a trained therapist</intervention_name>
    <description>Monthly assessments of functional motor abilities in adult 5q-SMA type 2 and type 3 patients by a trained therapist</description>
    <arm_group_label>5q-SMA type 2 and type 3 adults</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nusinersen</intervention_name>
    <description>nusinersen</description>
    <arm_group_label>5q-SMA type 2 and type 3 adults</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        inclusion criteria :&#xD;
&#xD;
          -  Adults (over 18 years of age)&#xD;
&#xD;
          -  5q-SMA type 2 or 3&#xD;
&#xD;
          -  with indication for nusinersen treatment by the physician of the center of reference&#xD;
             and competence for neuromuscular diseases&#xD;
&#xD;
          -  accepting treatment by nusinersen&#xD;
&#xD;
          -  Agreeing to participate in the study (signature of the informed consent form).&#xD;
&#xD;
          -  living within a radius of 40 km of the investigation center (for logistical reasons&#xD;
             related to the conduct of assessments in the patient's home).&#xD;
&#xD;
          -  affiliated to a social security system.&#xD;
&#xD;
        exclusion criteria :&#xD;
&#xD;
          -  minors (less than 18 years of age)&#xD;
&#xD;
          -  with a contra-indication to the nusinersen: pregnancy, breast feeding,&#xD;
             hypersensitivity to the nusinersen&#xD;
&#xD;
          -  with a contraindication to lumbar puncture: hemostasis disorder, intracerebral mass&#xD;
&#xD;
          -  benefiting from another gene therapy drug to treat spinal muscular atrophy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Francois BOYER</last_name>
    <phone>03 26 78 89 61</phone>
    <phone_ext>0033</phone_ext>
    <email>fboyer@chu-reims.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Damien JOLLY</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Francois BOYER</last_name>
      <phone>03 26 78 89 61</phone>
      <phone_ext>0033</phone_ext>
      <email>fboyer@chu-reims.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 29, 2020</study_first_submitted>
  <study_first_submitted_qc>October 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2020</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oligonucleotides</keyword>
  <keyword>survival of motor 2 protein</keyword>
  <keyword>muscular atrophy</keyword>
  <keyword>quality of life</keyword>
  <keyword>genetic therapy</keyword>
  <keyword>single-case studies as topic</keyword>
  <keyword>humans</keyword>
  <keyword>adult</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

